DVT-IMP - Deep Vein Thrombosis - Impedimetric Microanalysis System (FP6-IST) (2006-09-01 - 2009-08-31) (»add to infobox)

Zulfiqur ALI, N. N. BUDAPESTI MUSZAKI ES GAZDASAGTUDOMANYI EGYETEM, N. N. COMENIUS UNIVERSITY BRATISLAVA, N. N. FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG EV, N. N. FUNDACIO PRIVADA PARC CIENTIFIC DE BARCELONA, N. N. HAPTOGEN LIMITED, N. N. HELENA LABORATORIES (UK) LIMITED, N. N. THE CENTRE OF EXCELLENCE IN NANOTECHNOLOGY MICRO AND PHOTONIC SYSTEMS LIMITED, N. N. UNIVERSITE CLAUDE BERNARD LYON 1, N. N. UNIVERSITE DE PARIS-SUD XI

UNIVERSITY OF TEESSIDE (UK111 - Cleveland) (Great Britain), BUDAPESTI MUSZAKI ES GAZDASAGTUDOMANYI EGYETEM (HU101 - Budapest) (Hungary), COMENIUS UNIVERSITY BRATISLAVA (SK010 - Bratislavsky kraj) (Slovakia), FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG EV (DE212 - München, Kreisfreie Stadt) (Germany), FUNDACIO PRIVADA PARC CIENTIFIC DE BARCELONA (ES511 - Barcelona) (Spain), HAPTOGEN LIMITED (UKA40 - Grampian) (Great Britain), HELENA LABORATORIES (UK) LIMITED (UK132 - Tyne And Wear) (Great Britain), THE CENTRE OF EXCELLENCE IN NANOTECHNOLOGY MICRO AND PHOTONIC SYSTEMS LIMITED (UK132 - Tyne And Wear) (Great Britain), UNIVERSITE CLAUDE BERNARD LYON 1 (FR716 - Rhône) (France), UNIVERSITE DE PARIS-SUD XI (FR104 - Essonne) (France)

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) are major causes of unexpected mortality in hospitals throughout Europe. D-dimer is a recognised biomarker for the diagnosis of a thrombus and is routinely examined in hospital laboratories using a traditional ELISA technique. The clinical need for a fast predictive test for D-dimer has prompted the development of test kits, some of which are deployed at the point-of-care as a means of guiding clinicians. Current D-dimer point-of-care diagnostic kits do not provide accurate, quantitative analysis creating uncertainty amongst clinicians who are unable to exclude DVT/PE as a result, and consequently unnecessarily refer many patients for high-cost Doppler ultrasound imaging, creating pressure on healthcare services across Europe. The consortium, industrially driven by a leading healthcare supplies provider, incorporating skilled SMEs in electro-analysis instrumentation and bio-engineering and including academic bases in clinical pharmacology, microelectronics, analytical electrochemistry and micro-fabrication aims to integrate four key technologies areas: Bio-engineered antibodies for high specificity immunoassay diagnostics Nano/micro engineered impedimetric analysis electrodes incorporating bio-compatible conducting polymer substrates for enhanced detection capabilities Development and packaging of a disposable, sterile, microfluidic manifold enabling diagnostics at the point-of-care Developing e-Health diagnostic software toolkit for high positive and negative predictivity D-dimer tests DVT-IMP will innovation bio-nano/ micro-informatic technologies that will enable the development of a point-of-care device with advanced diagnostic capabilities, including the output of quantitative D-dimer levels, thus increasing confidence and certainty for clinicians, enabling them to confirm or exclude the risk of DVT/PE using the high negative and positive predictive capabilities of the DVT-IMP prototype

PERSONS (10/10)

RELATED NAVIGATION AREA(S) (1/1)